- Home
- GILD
GILD
Gilead Sciences Inc.
as 09-18-2025 4:00pm EST
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 139.6B | IPO Year: | 1992 |
| Target Price: | $116.36 | AVG Volume (30 days): | 5.9M |
| Analyst Decision: | Buy | Number of Analysts: | 23 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 5.01 | EPS Growth: | 496.80 |
| 52 Week Low/High: | $81.83 - $121.83 | Next Earning Date: | 11-05-2025 |
| Revenue: | $28,863,000,000 | Revenue Growth: | 3.81% |
| Revenue Growth (this year): | 2.07% | Revenue Growth (next year): | 3.95% |
Stock Insider Trading Activity of Gilead Sciences Inc. (GILD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dickinson Andrew D | GILD | Chief Financial Officer | Sep 15 '25 | Sell | $113.57 | 2,500 | $283,925.00 | 159,555 | |
| Mercier Johanna | GILD | Chief Commercial Officer | Sep 15 '25 | Sell | $113.57 | 3,000 | $340,710.00 | 113,193 | |
| O'Day Daniel Patrick | GILD | Chairman & CEO | Aug 28 '25 | Sell | $113.63 | 10,000 | $1,136,300.00 | 595,725 | |
| Dickinson Andrew D | GILD | Chief Financial Officer | Aug 15 '25 | Sell | $118.53 | 2,500 | $296,325.00 | 159,555 | |
| Mercier Johanna | GILD | Chief Commercial Officer | Aug 15 '25 | Sell | $118.74 | 28,000 | $3,318,926.70 | 113,193 |
Latest Gilead Sciences Inc. News
GILD Breaking Stock News: Dive into GILD Ticker-Specific Updates for Smart Investing
PR Newswire
11 hours ago
Marengo Therapeutics Advances STARt-002 Clinical Trial into Phase 2 Cohort Expansion Evaluating Invikafusp Alfa with TROP2-directed ADC TRODELVY® in Metastatic Breast Cancer
GlobeNewswire
21 hours ago
Fangzhou Wins Gilead ‘Award of Excellence’ for AI-Driven Chronic Disease Management
Zacks
a day ago
Gilead Sciences (GILD) Ascends While Market Falls: Some Facts to Note
GlobeNewswire
a day ago
Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis
MT Newswires
2 days ago
Gilead Sciences Insider Sold Shares Worth $340,710, According to a Recent SEC Filing
MT Newswires
2 days ago
Gilead Sciences Insider Sold Shares Worth $283,925, According to a Recent SEC Filing
Insider Monkey
2 days ago
Redburn Atlantic Maintains a Buy on Gilead Sciences (GILD), Sets a $143 PT
Business Wire
2 days ago
Top 20 Companies Recognized in Labrador Transparency’s 2025 U.S. Transparency Awards
Compare GILD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GILD Gilead Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.